|
IER2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.0898953374865E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.30800037467793E-10 |
| Normal-vs-Stage2 |
2.45859999026266E-09 |
| Normal-vs-Stage3 |
2.54279930445023E-11 |
| Normal-vs-Stage4 |
1.5671020037189E-11 |
| Stage1-vs-Stage2 |
3.878000E-01 |
| Stage1-vs-Stage3 |
2.052800E-01 |
| Stage1-vs-Stage4 |
1.159190E-01 |
| Stage2-vs-Stage3 |
8.181700E-02 |
| Stage2-vs-Stage4 |
5.174200E-02 |
| Stage3-vs-Stage4 |
5.379600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.99309474374832E-11 |
| Normal-vs-AfricanAmerican |
2.10829999999218E-05 |
| Normal-vs-Asian |
9.67619995240199E-09 |
| Caucasian-vs-AfricanAmerican |
5.925600E-01 |
| Caucasian-vs-Asian |
1.866030E-01 |
| AfricanAmerican-vs-Asian |
8.397400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.48719941811737E-11 |
| Normal-vs-Female |
1.00729979912728E-10 |
| Male-vs-Female |
3.765800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.8271946136208E-11 |
| Normal-vs-Age(41-60Yrs) |
5.42810241199732E-11 |
| Normal-vs-Age(61-80Yrs) |
1.4381995594448E-10 |
| Normal-vs-Age(81-100Yrs) |
1.4738999998265E-07 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.036600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.317600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.568600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.551200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.142200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.906200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.6069818766864E-12 |
| Classical-VS-Follicular |
5.859700E-03 |
| Classical-VS-Other |
8.703600E-01 |
| Classical-VS-Normal |
7.47020223457184E-11 |
| Tall-VS-Follicular |
5.55260282197878E-11 |
| Tall-VS-Other |
8.430400E-02 |
| Tall-VS-Normal |
1.69164682262135E-12 |
| Follicular-VS-Other |
4.864200E-01 |
| Follicular-VS-Normal |
9.59379997667043E-09 |
| Other-VS-Normal |
4.14319999997304E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.78519984853176E-10 |
| Normal-vs-N1 |
4.90999463309549E-11 |
| N0-vs-N1 |
2.031600E-01 |
|
|
